論文 - 結城 敏志
-
HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment
Ito, K; Yuki, S; Nakano, S; Yagisawa, M; Sawada, K; Ishiguro, A; Muto, O; Hatanaka, K; Okuda, H; Sato, A; Sasaki, Y; Nakamura, M; Sasaki, T; Kobayashi, T; Dazai, M; Nakatsumi, H; Ueda, A; Tateyama, M; Sogabe, S; Matsumoto, R; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 32 S108 - S108 2021年07月
-
Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).
Saito, R; Kawamoto, Y; Yuki, S; Sogabe, S; Dazai, M; Hosokawa, A; Sawada, K; Sato, A; Nakamura, M; Hatanaka, K; Ishiguro, A; Muto, O; Shindo, Y; Tsuji, Y; Tateyama, M; Ueda, A; Sasaki, T; Katagiri, M; Sakamoto, N; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 39 ( 15 ) 2021年05月
-
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer
Takahashi, S; Sakamoto, Y; Denda, T; Takashima, A; Komatsu, Y; Nakamura, M; Ohori, H; Yamaguchi, T; Kobayashi, Y; Baba, H; Kotake, M; Amagai, K; Kondo, H; Shimada, K; Sato, A; Yuki, S; Okita, A; Ouchi, K; Komine, K; Watanabe, M; Morita, S; Ishioka, C
CANCER SCIENCE 112 ( 4 ) 1567 - 1578 2021年04月
-
Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
Kawamoto, Y; Yuki, S; Sawada, K; Nakamura, M; Muto, O; Sogabe, S; Shindo, Y; Ishiguro, A; Sato, A; Tsuji, Y; Dazai, M; Okuda, H; Sasaki, T; Harada, K; Nakano, S; Nakatsumi, H; Sekiguchi, M; Sakata, Y; Sakamoto, N; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 39 ( 3 ) 2021年01月
-
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
Nakano, S; Kawamoto, Y; Yuki, S; Harada, K; Sogabe, S; Dazai, M; Sato, A; Ishiguro, A; Nakamura, M; Kajiura, S; Takahashi, Y; Karasaki, H; Tateyama, M; Hatanaka, K; Tsuji, Y; Sasaki, T; Shindo, Y; Kobayashi, T; Sakata, Y; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 15 ) 2020年05月
-
Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
Yuki, S; Gamoh, M; Denda, T; Takashima, A; Takahashi, S; Nakamura, M; Ohori, H; Yamaguchi, T; Kobayashi, Y; Baba, H; Kotake, M; Amagai, K; Kondo, H; Shimada, K; Sato, A; Ishioka, C; Komine, K; Ouchi, K; Morita, S; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 4 ) 2020年02月
-
HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapy-Updated analysis of antitumor efficacy
Ishiguro, A; Nakatsumi, H; Muranaka, T; Kawamoto, Y; Yuki, S; Tateyama, M; Sato, A; Miyagishima, T; Nakamura, M; Dazai, M; Okuda, H; Takahashi, Y; Kobayashi, T; Kato, T; Hatanaka, K; Amano, T; Sakata, Y; Komatsu, Y
JOURNAL OF CLINICAL ONCOLOGY 38 ( 4 ) 2020年02月
-
HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Tanimoto, A; Yagisawa, M; Nakano, S; Kawamoto, Y; Yuki, S; Ishiguro, A; Takahata, T; Sato, A; Iwanaga, I; Ehira, N; Uebayashi, M; Muto, O; Sasaki, T; Hatanaka, K; Tateyama, M; Wakabayashi, T; Dazai, M; Minami, S; Sakata, Y; Komatsu, Y
ANNALS OF ONCOLOGY 30 2019年11月